Overview
- Trump cited a target of about $150 per month for Ozempic and similar GLP-1 medicines, far below current U.S. list prices and typical cash offers.
- CMS Administrator Dr. Mehmet Oz clarified that no GLP-1 pricing agreements have been finalized and that negotiations are ongoing.
- Novo Nordisk said it is in discussions with the administration under the Most Favored Nation executive order, following earlier pricing deals with Pfizer and AstraZeneca.
- Shares of Novo Nordisk and Eli Lilly fell in U.S. and European trading after the remarks, while Hims & Hers also declined on concerns about competition with lower cash prices.
- Key details on timing, implementation, and the impact on access and manufacturer revenues remain unsettled as the talks continue.